Top

Published in:

01-04-2015 | Research

Trends and Present Treatment Patterns of Early Breast Cancer in Southwest China

Authors: Qiancheng Hu, Ting Luo, Ping He, Xiaorong Zhong, Tinglun Tian, Qing Lv, Xi Yan, Hong Zheng

Published in: Pathology & Oncology Research | Issue 2/2015

Abstract

To analyze the changing patterns of treatment and to explore the current treatment approaches for breast cancer in Southwest China, we conducted a population-based retrospective cohort study of early breast cancer cases. The data of patients who registered in the information management system for breast cancer in Huaxi Hospital, Sichuan University from 1989 to 2012 were extracted. Nearly all patients underwent surgery, among whom radical mastectomy was the predominant option. Chemotherapy (88.7 %) was the most predominant adjuvant therapy approach. The percentage of patients receiving radiation therapy displayed fluctuant increase, which was 37.1 % in 2001 and reached up to 67.6 % in 2011. Besides, the endocrinetherapy became more and more popular in the hormone-receptor positive patients and the percentage of endocrinetherapy was increased from 54.1 at 2001 to 85.6 % at 2011. However, more than 10 % of hormone-receptor positive patients still did not receive endocrinetherapy annually. The hormone-receptor positive patients who received endocrinetherapy had better 5-year disease free survival (DFS) and overall survival (OS) compared to those without endocrinetherapy (5-y DFS: 88.4 % vs. 75.1 %, P < 0.001; 5-y OS: 95.7 % vs. 88.4 %, P < 0.001). N stage appeared to have greater impact on the 5-year DFS and OS than molecular subtyping. The treatment for breast cancer in China has been significantly improved but more attentions should be paid to radiotherapy and endocrine therapy. In addition, the value of N stage in the prognosis of breast cancer should not be ignored when the molecular typing draws more and more attentions.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMed

Huang X-E, Hirose K, Wakai K et al (2004) Comparison of lifestyle risk factors by family history for gastric, breast, lung and colorectal cancer. Asian Pac J Cancer Prev 5:419–427PubMed

Jemal A, Center MM, Desantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893–1907CrossRefPubMed

Fan L, Zheng Y, Yu KD et al (2009) Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat 117:409–416CrossRefPubMed

Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792CrossRefPubMed

Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241CrossRefPubMed

Ctsu RI (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef

Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62CrossRefPubMed

Thürlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757CrossRefPubMed

10.

Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092CrossRefPubMed

11.

Eggemann H, Ignatov A, Smith BJ et al (2013) Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137:465–470CrossRefPubMed

12.

Perez EA, Romond EH, Suman VJ et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2–positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366–3373CrossRefPubMedCentralPubMed

13.

Welslau M, Dieras V, Sohn JH et al (2014) Patient-reported outcomes from EMILIA, a randomized phase 3 study of Trastuzumab Emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer-Am Cancer Soc 120:642–651

14.

Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD (1995) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87:1441–1445CrossRefPubMed

15.

Goldhirsch A, Glick JH, Gelber RD, Senn HJ (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601–1608CrossRefPubMed

16.

Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ (2001) Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 19:3817–3827PubMed

17.

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365CrossRefPubMed

18.

Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583CrossRefPubMed

19.

Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329CrossRefPubMedCentralPubMed

20.

Hammond ME, Hayes DF, Dowsett M et al (2010) American society of clinical oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48–72PubMed

21.

Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747CrossRefPubMedCentralPubMed

22.

Network NCC, NCCN clinical practice guidelines in oncology: breast cancer (2007) National comprehensive cancer network

23.

Harbeck N, Jakesz R (2007) St. Gallen 2007: breast cancer treatment consensus report. Breast Care 2:130–134CrossRef

24.

Parkin DM, Fernández LM (2006) Use of statistics to assess the global burden of breast cancer. Breast J 12:S70–S80CrossRefPubMed

25.

Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502CrossRefPubMed

26.

Xue C, Wang X, Peng R et al (2012) Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci 103:1679–1687CrossRefPubMedCentralPubMed

27.

Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874CrossRefPubMedCentralPubMed

28.

Kurebayashi J, Moriya T, Ishida T et al (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. The Breast 16:72–77CrossRef

29.

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype. Cancer 109:1721–1728CrossRefPubMed

30.

Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657CrossRefPubMed

31.

Zhao J, Liu H, Wang M et al (2009) Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Clin Oncol 100:89–94

32.

Panjwani P, Epari S, Karpate A et al. (2010) Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: experience of a tertiary cancer referral centre in India

33.

Press MF, Sauter G, Bernstein L et al (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598–6607CrossRefPubMed

34.

Yu K-D, Li S, Shao Z-M (2011) Different annual recurrence pattern between lumpectomy and mastectomy: implication for breast cancer surveillance after breast-conserving surgery. Oncologist 16:1101–1110CrossRefPubMedCentralPubMed

35.

Smith GL, Xu Y, Shih Y-CT et al (2009) Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States. J Am Coll Surg 209:425–433. e422CrossRefPubMed

36.

Li J, Zhang B-N, Fan J-H et al (2011) A Nation-Wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in china. BMC Cancer 11:364CrossRefPubMedCentralPubMed

37.

Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283CrossRefPubMedCentralPubMed

38.

Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529–537CrossRefPubMedCentralPubMed

39.

Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen. Cancer 109:832–839CrossRefPubMed

40.

Baum M, Budzar A, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139CrossRefPubMed

41.

Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816PubMed

42.

Dixon JM, Jackson J, Hills M et al (2004) Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 40:2742–2747CrossRefPubMed

43.

Ihemelandu CU, Leffall LD Jr, Dewitty RL et al (2007) Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Oncol 143:109–118

44.

Wang GS, Zhu H, Bi SJ (2012) Pathological features and prognosis of different molecular subtypes of breast cancer. Mol Med Report 6:779–782

Title: Trends and Present Treatment Patterns of Early Breast Cancer in Southwest China
Authors: Qiancheng Hu
Ting Luo
Ping He
Xiaorong Zhong
Tinglun Tian
Qing Lv
Xi Yan
Hong Zheng
Publication date: 01-04-2015
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-014-9829-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

The Apoptotic Effect of Plant Based Nanosilver in Colon Cancer Cells is a p53 Dependent Process Involving ROS and JNK Cascade

Tumor Necrosis Factor Alpha (−238 / −308) and TNFRII-VNTR (−322) Polymorphisms as Genetic Biomarkers of Susceptibility to Develop Cervical Cancer Among Tunisians

High Phosphorylation Status of AKT/mTOR Signal in DESI2-Reduced Pancreatic Ductal Adenocarcinoma

The Evaluation of WBP2NL-Related Genes Expression in Breast Cancer

Pericardial Tamponade Caused by Tumor Hemorrhage – a Rare Complication of Metastatic Testicular Choriocarcinoma

Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations

Keynote webinar | Spotlight on antibody–drug conjugates in cancer